Rutter WC, Burgess DR, Talbert JC, et al: Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A ret- rospective cohort analysis. J Hosp Med 2017; 12:77-82Rutter, W. Cliff,Burgess,etc.Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin-...
Single-dose vials of piperacillin/tazobactam (Zosyn, generic): Reconstitute vials containing 2.25 g (2 g of piperacillin and 0.25 g of tazobactam), 3.375 g (3 g of piperacillin and 0.375 g of tazobactam), or 4.5 g (4 g of piperacillin and 0.5 g of tazobactam) by adding 10, 15, or ...
Piperacillin-Tazobactam vs Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy View LargeDownload Figure 1. Participant Flow in a Study of Piperacillin-Tazobactam vs Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy View LargeDownload aRandomization stratified by the presence or ...
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally... The in vitro activity of piperacillin/tazobactam and several comparison broad-spectrum compounds was assessed against recent clinical isolates of Gram...
Vancomycin Trough Concentrations Among Recipients of Vancomycin Plus Piperacillin/Tazobactam or Vancomycin Plus Other Antipseudomonal Beta-Lactam Agents eTable 4. Sensitivity Analysis of the Effect of an Unmeasured Confounder on the Association Between Combination Therapy Group and AA-AKI eTable 5. Multip...
Objective: To determine the incidence of acute renal failure following the co-administration of vancomycin and piperacillin/tazobactam in surgical intensive care unit patients. Methods: Medical records of patients admitted to a surgical intensive care unit at an academic medical center were reviewed. Adu...
尾-lactam/尾-lactamase inhibitor combinations or carbapenems are often used to ensure coverage of likely pathogens. Piperacillin/tazobactam is proposed as a carbapenem-sparing agent to reduce the incidence of multidrug-resistant bacteria and superinfections. In the recently published MERINO trial, ...
We compared the efficacy and safety of initial empiric therapy with piperacillin/tazobactam (PIPC/TAZ, 13.5g/day) with that of meropenem (MEPM, 1.5g/day) as single broad-spectrum regimens with gram-negative and anaerobic coverage in patients with HCAP in Japan. The clinical cure rate was ...
Conclusions and Relevance Among patients with suspected sepsis and no clear indication for antianaerobic coverage, administration of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared with cefepime. These findings suggest...
We chose Piperacillin-Tazobactam (P-T) based on known nosocomial bacterial flora. We evaluated the impact of P-T based strategy on patient exposure to antibiotics, ICU length of stay (LOS), and incidence of resistant (R) organisms to P-T within 30 days post-op. Methods and Materials We ...